Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.
26 May, 2022 | 10:30h | UTCSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Endocrine therapy is used in clinical practice in the management of relapsed or advanced HR + endometrial cancer. Anastrozole + vistusertib demonstrated clinically significant improvement with manageable adverse events, encouraging further research https://t.co/hHDtloSdNs #GynCSM
— JAMA Oncology (@JAMAOnc) May 12, 2022